Successful Treatment of Diabetic Foot Osteomyelitis with Dalbavancin
Authors:
Open Access
- 1 January 2020
- journal article
- research article
- Published by ScopeMed in Medical Archives
- Vol. 74 (3) , 243-245
Abstract
Dalbavancin is a new antibiotic against multi-drug resistant Gram (+) bacteria. Dalbavancin has an extremely long half-life. Current indication is skin and soft tissue infections (ABSSSI), but researchers have successfully administered it off-label to osteomyelitis (OM) patients. We present a case of successful treatment of diabetic foot (DF) OM. A 53-year-old male presented to our DF clinic, with recently diagnosed diabetes mellitus, with very bad glycaemic control (HbA1c=12,5%). He had diabetic neuropathy, but no peripheral arteriopathy. Two months before, because of an accident with hot water, he presented left foot ulcer, followed by ABSSSI and 1st toe and 1st metatarsal OM (plain x-ray findings). A multi-drug resistant Enterococcus faecium was isolated in cultures and a targeted treatment with tigecycline and daptomycin was administered. The patient also received 1,5 gr dalbavancin upon discharge. 2 weeks later, he continued treatment at home with linezolid and tedizolid. A complete medical record with patient’s history, informed consent and relative literature was sent to Greek National Health Care Organization (EOPYY), requesting administering off-label another 1,5 gr dalbavancin. In the meanwhile, he was admitted for iv tigecyclin, and continued treatment with linezolid at home. He finally received a second dose of 1,5 g dalbavancin. Patient received totally 14 weeks’ targeted therapy, mostly off-hospital. When he completed treatment, foot was in excellent condition and x-ray had significantly improved. Dalbavancin, due to its extremely long half-life, could potentially be the drug of choice for OM caused by multi-drug resistant Gram (+) cocci, in order to avoid hospitalization, especially on non-complient patients. Further research is necessary.Keywords
This publication has 9 references indexed in Scilit:
- Dalbavancin in the treatment of different gram-positive infections: a real-life experienceInternational Journal of Antimicrobial Agents, 2018
- A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure InfectionClinical Infectious Diseases, 2015
- Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative ReviewDrugs, 2015
- Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular TissueAntimicrobial Agents and Chemotherapy, 2015
- Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: A plea for implementation of early switch and early discharge criteriaInternational Journal of Antimicrobial Agents, 2014
- Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin InfectionNew England Journal of Medicine, 2014
- Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007)Diagnostic Microbiology and Infectious Disease, 2009
- Activities of Dalbavancin against a Worldwide Collection of 81,673 Gram-Positive Bacterial IsolatesAntimicrobial Agents and Chemotherapy, 2009
- Origin, structure, and activity in vitro and in vivo of dalbavancinJournal of Antimicrobial Chemotherapy, 2005